Dr. Erika Haydu

#Lymphoma physician and clinical investigator @MGHCancerCenter, by way of @MGH @DanaFarber @BrighamWomens @ColumbiaPS @WilliamsCollege | views my own

[Dr. Erika Haydu @ErikaHaydu]

We walk through the current landscape and recent approvals for CAR T and BsAb in large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma.

[Dr. Erika Haydu @ErikaHaydu]

Excited to see our CAR T-cell and bispecific antibody review in print! @JSALymphomaDoc @BloodAdvances @MGHCancerCenter https://t.co/HWXgNDxkRA

[Dr. Erika Haydu @ErikaHaydu]

Catch up on leukemia and lymphoma advances in Boston October 12! Link to register below.

[Gaby Hobbs @GabyHobbs]

Look forward to chairing the upcoming @OncLiveSOSS discussing leukemia + lymphoma with this all⭐️ crew @Mark_Leick @pconnorjohnson and @ErikaHaydu Oct. 12, 6-9 pm at the W Boston #MGHCancerCenter #mpnsm. Register here👉https://t.co/sSYJZeJReD

[Dr. Erika Haydu @ErikaHaydu]

Love my Brigham residency family! @BrighamMedRes @BrighamWomens

[Diana López, MD @DMLopez5]

Amazing start to the @BrighamMedRes Reunion Weekend with our 2016 Intern Class Dinner! Yes, we were those rowdy interns at Mouse Club 😉. Thanks to @ErikaHaydu for hosting us!

[Dr. Erika Haydu @ErikaHaydu]

@BrighamMedRes reunion!!!

[Diana López, MD @DMLopez5]

Amazing start to the @BrighamMedRes Reunion Weekend with our 2016 Intern Class Dinner! Yes, we were those rowdy interns at Mouse Club 😉. Thanks to @ErikaHaydu for hosting us!

[Dr. Erika Haydu @ErikaHaydu]

Amazing experience thanks @lymphoma, organizers, mentors, and my fellow scholars!

[Lymphoma Research Foundation @lymphoma]

We’re wrapping up the Spring 2023 Lymphoma Scientific Research Mentoring Program (LSRMP) Workshop! LRF’s LSRMP is an education & mentoring program for junior scientists focusing on #lymphoma research. To learn more about LRF's research program, visit us: https://t.co/81hZN9dVwB

[Dr. Erika Haydu @ErikaHaydu]

Excited to see this in print! @IrunBhanMD @MGHMedicine @MassGeneralNews

[NEJM @NEJM]

Case Records of the Massachusetts General Hospital: A 56-Year-Old Man with Abnormal Results on Liver Testing

https://t.co/IuYes4Dwpu

[Dr. Erika Haydu @ErikaHaydu]

Our very own @JSALymphomaDoc @MGHCancerCenter !

[The ASCO Post @ASCOPost]

A Serendipitous Opportunity Steers a Theater Major Into Oncology: Profile of Jeremy S. Abramson, MD https://t.co/VX0BjrebPA @JSALymphomaDoc @MGHCancerCenter

[Dr. Erika Haydu @ErikaHaydu]

Very interesting work in CH by @Lachelle_Dawn #ASH22

[Dana-Farber @DanaFarber]

Research by Dana-Farber led to the development of CHRS, a clinical tool to assess the risk of progression in patients with clonal hematopoiesis (CH), a common precursor to myeloid malignancies. Lachelle Weeks, MD, PhD, (@Lachelle_Dawn), discusses the findings presented at #ASH22.

[Dr. Erika Haydu @ErikaHaydu]

Great presentation @jdsoumerai #ASH22

[Dr. Erika Haydu @ErikaHaydu]

Excellent study looking at PROs with CART @pconnorjohnson #ASH22

[VJHemOnc @VJHemOnc]

We had a great interview this morning with Jeremy Abramson of @MGHCancerCenter on the role of bispecifics and CAR-T cells in R/R DLBCL, the TRANSFORM trial, and more!

@ASH_hematology #ASH22 #DLBCL #LymSM #ImmunoOnc #CARTcell

[Dr. Erika Haydu @ErikaHaydu]

Important data on liso-cel 2L in DLBCL #ASH22

[Lymphoma Hub @lymphomahub]

CONGRESS | #ASH22 Jeremy Abramson, MD @MGHCancerCenter presents data on liso-cel vs SOC + salvage chemo + ASCT as 2L treatment in patients with R/R LBCL (TRANSFORM study). Liso-cel demonstrated statistically significant benefits to EFS, CR rate and PFS.
#lymsm #medicalcongress

[Dr. Erika Haydu @ErikaHaydu]

Great presentation @ChristineRyanMD #ASH22

[Dana-Farber News @DanaFarberNews]

Presenting her findings to a packed auditorium, @DanaFarber Christine Ryan, M.D. explains how a triple regimen of AVO was shown highly effective in patients with high-risk forms of Chronic Lymphocytic Leukemia. #ASH22

[Dr. Erika Haydu @ErikaHaydu]

Congrats @beckyzon #ASH22

[Christine Ryan, MD @ChristineRyanMD]

Huge congratulations to my amazing co-fellow and friend @beckyzon on her #ASH22 presentation on a highly effective implementation of EMR alerts to improve management of HIT! @BrighamHeme @DanaFarber

[Mass General Brigham Research @MGBResearchNews]

Researchers from @MGHCancerCenter and colleagues find liso-cel as a second-line treatment for early relapsed or refractory LBCL, in a @TheLancet study. https://t.co/iXp03Ps2sF

[Dr. Erika Haydu @ErikaHaydu]

Fantastic opportunity @HerranzLab if you’re looking for a research technician job!

[Dr. Erika Haydu @ErikaHaydu]

Looking forward to this ASH trainee council podcast series #womeninhematology @beckyzon and others @BloodJournal @BloodAdvances

[Becky Zon, MD @beckyzon]

Check out the ASH Trainee Council Women in Hematology 3-part Podcast series! Hear inspiring interviews by Dr. Nancy Berliner, Dr. @AMarshallMD, and (coming soon) Dr. @nadahamad! 🩸❤️ @NinaOncMD and I host!😍

Thanks @majorajay, @NODlike, @Midenightrosemh and the whole TC crew!

[Dr. Erika Haydu @ErikaHaydu]

Excited to see this in press! Great collaborative effort.

[Dr. Erika Haydu @ErikaHaydu]

Great article @sacjai about @BrighamWomens IM residency program leader @DrJoelKatz who "recruit[ed] for talent and heart... Heart for patients, heart for community, heart for colleagues"

[Sachin H. Jain, MD, MBA @sacjai]

Last week, @DrJoelKatz announced his decision to step down as leader of @BrighamWomens famed internal medicine training program. I wrote about lessons I learned from him about how to build and sustain a winning clincial culture for my column in @Forbes.

https://t.co/fx0rAJrhUa